[{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Neurology","graph2":"Phase I","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliPass \/ Not Applicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Novotech"},{"orgOrder":0,"company":"OliPass","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"mRNA","graph1":"Technology","graph2":"Preclinical","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"OliPass \/ OliPass","highestDevelopmentStatusID":"4","companyTruncated":"OliPass \/ OliPass"},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Not Applicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by OliPass

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthrit...

                          Brand Name : OLP-1002

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 13, 2023

                          Lead Product(s) : OLP-1002

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthrit...

                          Brand Name : OLP-1002

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 16, 2023

                          Lead Product(s) : OLP-1002

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration will focus on editing and modifying gene expression using ASOs in disease states where the expression of genes is either altered or the sequence of the expressed genes can be altered for therapeutic benefit.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 29, 2022

                          Lead Product(s) : Antisense Oligonucleotide

                          Therapeutic Area : Technology

                          Highest Development Status : Preclinical

                          Recipient : Vanda Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and therefore expected to replicate much of the phenotype of people with SCN9A channelopathy.

                          Brand Name : OLP-1002

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 18, 2022

                          Lead Product(s) : OLP-1002

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Novotech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OLP-1002 manifested excellent safety in a UK Phase 1 study evaluated in a total of 116 healthy volunteers. In the meantime, an exploratory Phase 1b study in Australia suggested clues to strong efficacy and long therapeutic duration in OA patients.

                          Brand Name : OLP-1002

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 25, 2021

                          Lead Product(s) : OLP-1002

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank